Table 1.

Patient characteristics

	n (%)
Number of patients evaluable	184
Time from original protocol registration to 05-159, years, median (range)	7.0 (1.1–17.1)
Sex
Male	101 (55)
Female	83 (45)
Age at diagnosis, median (range)	6.3 (<1–17.9)
<10 years	109 (59)
≥10 years	75 (41)
Age at time of enrollment on DFCI Protocol 05-159, median (range)	15.2 (3.1–31.4)
<10 years	44 (24)
≥10 years	140 (76)
Immunophenotype at diagnosis
T-cell	34 (18)
B-cell	150 (82)
White blood cell count at diagnosis (k/μl), median (range)	20.1 (1.3–740.4)
Serum iron concentration (μg/dL)†	75.0 (15.0–235.0)
Serum ferritin concentration (ng/mL)†	67.2 (7.21–1998.0)
Treatment
Doxorubicin	68 (37)
Dexrazoxane before doxorubicin	116 (63)
Cumulative doxorubicin dose (mg/m2), median (range)	300 (204–420)
Time from registration on original protocol to post-baseline echocardiogram, years, median (range)	6.1 (1.0–16.1)
No. Echocardiograms
T1 (1–3.99 yrs from Registration)	95 (52)
T2 (4–6.99 yrs from Registration)	53 (29)
T3 (7+ yrs from Registration)	47 (26)

^†Data from only 97 patients available. T=time.